Abstract
We assessed hospitalisations for gastrointestinal bleeding directly related to primary prevention aspirin in lower risk patients for a 6-month period in three South Australian hospitals. Those with related underlying pathology or concurrent causative medication were excluded. Identified patients (n = 22) carried little co-morbidity, 41% received prior proton-pump inhibitors and 68% were aged >70 years. Mean hospital admission cost was $6769 (95% confidence interval $5198–$8340), with projected state and national annual costs of $0.57 and $8.12 million respectively. In light of recent guideline changes, clinicians need to vigorously assess the need for primary prevention aspirin.
Original language | English |
---|---|
Pages (from-to) | 318-321 |
Number of pages | 4 |
Journal | Internal Medicine Journal |
Volume | 52 |
Issue number | 2 |
DOIs | |
Publication status | Published or Issued - Feb 2022 |
Externally published | Yes |
Keywords
- adverse drug reaction
- aspirin
- cost
- deprescribing
- gastrointestinal bleeding
- primary prevention
ASJC Scopus subject areas
- Internal Medicine